Featured Research

from universities, journals, and other organizations

First-in-class drug tested in patients with advanced cancer; targets stem-like properties of certain cancer cells

Date:
April 21, 2010
Source:
American Association for Cancer Research
Summary:
Researchers are working to develop a novel first-in-class cancer drug that works by targeting the stem-like properties of some cancer cells, and so far, results of an ongoing Phase I clinical trial demonstrate early signs of a strong safety profile and clinical activity.

Researchers at Boston Biomedical, Inc., are working to develop a novel first-in-class cancer drug that works by targeting the stem like properties of some cancer cells, and so far, results of an ongoing Phase I clinical trial demonstrate early signs of a strong safety profile and clinical activity.

Related Articles


"Cancer stem cells arguably represent one of the hottest frontiers in cancer research today," said Chiang J. Li, M.D., chairman and chief executive officer of Boston Biomedical, Inc., Norwood, Mass., who led the research discovery. "If the cancer stem cell hypothesis is proven to be correct, it should be possible to fundamentally advance treatment for patients with a wide variety of cancers because these highly malignant cell populations are inherently resistant to conventional therapies."

Updated data will be presented during the late-breaking clinical trial symposium at the AACR 101st Annual Meeting 2010, held April 17-21.

Li and colleagues took an unconventional line of attack by developing BBI608, a first-in-class cancer cell stemness inhibitor that can target highly malignant cancer stem cells as well as other heterogenous cancer cells.

"Current debates or controversies regarding the cancer stem cell hypothesis are less relevant to our approach since we believe it is crucial to target all malignant cells," said Li.

The Phase I study of BBI608 was designed to determine its safety and to establish a dose regimen for Phase II trials in adult patients with various advanced cancers. The study is being conducted at the Segal Cancer Center, Montreal, Quebec, Canada; the Juravinski Cancer Center, Hamilton, Ontario, Canada; and the Karmanos Cancer Center, Detroit, Mich.

As of March 26, 2010, 18 cancer patients with various solid tumors were enrolled in the study.

Treatment with BBI608 consisted of twice-daily, oral administration for four-week cycles. Dose escalation of BBI608 has reached a daily regimen of 600 mg, and the blood concentration of BBI608 has exceeded the level required to kill cancer stem cells and heterogeneous cancer cells in the laboratory.

Patients have tolerated the escalating doses of BBI608 very well with no significant drug-related side effects. To date, nine patients were evaluated for antitumor activity, of which six have achieved stable disease for at least two months with early signs of tumor regression and prolonged stable disease.

"We are encouraged by the early clinical data which supports our further efforts targeting cancer cell stemness," Li said. "Through incredible team effort and hard work we have accomplished the discovery of BBI608, and its translation from bench to bedside in less than 24 months, which, to our knowledge, sets a record pace for translational medicine. We are very excited about our novel approach and the therapeutic potential of cancer cell stemness inhibitors."


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "First-in-class drug tested in patients with advanced cancer; targets stem-like properties of certain cancer cells." ScienceDaily. ScienceDaily, 21 April 2010. <www.sciencedaily.com/releases/2010/04/100419162117.htm>.
American Association for Cancer Research. (2010, April 21). First-in-class drug tested in patients with advanced cancer; targets stem-like properties of certain cancer cells. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2010/04/100419162117.htm
American Association for Cancer Research. "First-in-class drug tested in patients with advanced cancer; targets stem-like properties of certain cancer cells." ScienceDaily. www.sciencedaily.com/releases/2010/04/100419162117.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins